Abstract LB-226: Depletion of kynurenine using an engineered therapeutic enzyme potently inhibits cancer immune checkpoints both as a monotherapy and in combination with anti-PD-1

犬尿氨酸 免疫系统 癌症 药理学 黑色素瘤 癌症研究 癌细胞 肿瘤微环境 医学 免疫学 化学 内科学 生物化学 色氨酸 氨基酸
作者
Everett Stone,Nicholas Marshall,Moses Donkor,Kendra Triplett,John Blazek,Todd Triplett,Lauren I. R. Ehrlich,George Georgiou
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:75 (15_Supplement): LB-226 被引量:5
标识
DOI:10.1158/1538-7445.am2015-lb-226
摘要

Abstract Introduction: The kynurenine pathway is of key importance for immune suppression in cancer, a function exerted primarily via kynurenine as an AhR ligand that potently impairs adaptive immune responses. Inhibition of kynurenine (Kyn) synthesis, mediated by IDO1, TDO (and possibly IDO2) is of great interest for cancer immune checkpoint inhibition, with 3-4 IDO1 inhibitors currently in clinical development. However: (1) IDO1 inhibition has marginal anti-cancer effects as a monotherapy; (2) IDO1 inhibitors only block one of the two major pathways for Kynureine synthesis (the other being via TDO) and (3) IDO1 inhibition does generally not impact the serum concentration of Kynurenine and thus no pharmacodynamic marker is available. Experimental: We postulated that administration of a therapeutic enzyme (Kynureninase) that can degrade Kyn into non-toxic and immunologically inactive metabolites (Alanine and anthranilic acid) may be able to: (a) potently relieve cancer immune suppression. An extensive protein engineering campaign was carried out to develop a Kynureninase suitable for therapeutic administration which was then PEGylated (Kynase-PEG) to enable long circulation persistence. Kynase-PEG was evaluated in the well-established B16-OVA melanoma model in wild type C57BL/6J mice as a monotherapy and in combination with anti-PD-1 administration. Quantitation of tumor size/regression, histology, as well as flow cytometric analyses assessing lymphocytes in the spleen, tumor (TILs) and tumor-draining lymph nodes (dLNs) was used to evaluate efficacy. Summary: Administration of KYNase-PEG in B16-OVA melanoma allografts in C57BL/6J mice reduced serum Kyn levels and resulted in significant tumor growth retardation and extended survival in a manner indistinguishable from that observed with immune checkpoint inhibitors anti-PD1 (clone RMP1-14) or anti-CTLA-4 (clone 9D9) antibodies. KYNase-PEG administration did not display anti-tumor activity in NOD-scid Il2Rγ-/- mice or in IDO1-/- mice revealing that the function of the enzyme is dependent on adaptive immune responses and also on the function of stromal IDO1. Consistent with the hypothesis that depletion of Kyn relieves immune inhibition, we observed a marked increase in CD8+ TILs expressing Gzm B + IFNγ, enhanced proliferation of CD4+ and CD8+ T cells in the tumor dLNs as well as changes in tumor neovascularization. Importantly, combination of KYNase-PEG and anti-PD-1 administration resulted in complete tumor eradication in 60% of the animals (n = 10 per group) for >100 days, with all the surviving animals completely rejecting tumors following re-challenge. For comparison, anti-PD-1 treatment alone, only led to 20% long-term survival in this model. Conclusions: We demonstrated that unlike IDO1 inhibitors, KYNase-PEG displays a significant anti-tumor efficacy as a monotherapy as well as excellent synergism with anti-PD1. The observed increase in tumor infiltration and proliferation of cytotoxic CD8+ T cells argues that the mechanism of action of Kynase-PEG acts by relieving the immune suppression that normally occurs in the tumor microenvironment as a consequence of Kyn accumulation. Thus, KYNase-PEG represent a “first in class” immune checkpoint enzyme. Progress in developing a clinical candidate enzyme will be discussed. Citation Format: Everett Stone, Nicholas Marshall, Moses Donkor, Kendra Triplett, John Blazek, Todd Triplett, Lauren Ehrlich, George Georgiou. Depletion of kynurenine using an engineered therapeutic enzyme potently inhibits cancer immune checkpoints both as a monotherapy and in combination with anti-PD-1. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr LB-226. doi:10.1158/1538-7445.AM2015-LB-226

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Wang发布了新的文献求助10
刚刚
55555发布了新的文献求助20
刚刚
Echo1128完成签到 ,获得积分10
刚刚
1秒前
cocolu应助科研小白采纳,获得10
2秒前
Kenzonvay发布了新的文献求助10
2秒前
ussiMi完成签到 ,获得积分10
2秒前
李爱国应助美好的黛丝采纳,获得20
3秒前
NexusExplorer应助冷艳灵萱采纳,获得10
4秒前
PeterParker完成签到 ,获得积分10
5秒前
慕冬菱发布了新的文献求助10
6秒前
Nicy发布了新的文献求助10
7秒前
李健应助玩命的谷南采纳,获得10
8秒前
墨橙完成签到,获得积分10
9秒前
10秒前
SDSD完成签到,获得积分10
10秒前
10秒前
monned完成签到 ,获得积分10
12秒前
12秒前
所所应助Wang采纳,获得10
14秒前
sh完成签到 ,获得积分10
15秒前
pakkkho发布了新的文献求助10
16秒前
溪风完成签到,获得积分10
16秒前
17秒前
晊恦发布了新的文献求助10
17秒前
18秒前
zhaoyingxin发布了新的文献求助10
20秒前
SEV完成签到,获得积分10
20秒前
锐哥发布了新的文献求助10
22秒前
研友_VZG7GZ应助pakkkho采纳,获得10
23秒前
SEV发布了新的文献求助10
23秒前
23秒前
yellowonion完成签到 ,获得积分10
26秒前
chosmos发布了新的文献求助10
27秒前
SciGPT应助SDSD采纳,获得10
27秒前
脑洞疼应助zhaoyingxin采纳,获得20
28秒前
31秒前
情怀应助蜉蝣采纳,获得10
31秒前
Chenhao_Wang完成签到 ,获得积分10
31秒前
yqcsysu完成签到 ,获得积分10
32秒前
高分求助中
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger Heßler, Claudia, Rud 1000
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 1000
Natural History of Mantodea 螳螂的自然史 1000
A Photographic Guide to Mantis of China 常见螳螂野外识别手册 800
Barge Mooring (Oilfield Seamanship Series Volume 6) 600
ANSYS Workbench基础教程与实例详解 500
Spatial Political Economy: Uneven Development and the Production of Nature in Chile 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 内科学 物理 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 免疫学 细胞生物学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 3325288
求助须知:如何正确求助?哪些是违规求助? 2955988
关于积分的说明 8578548
捐赠科研通 2633885
什么是DOI,文献DOI怎么找? 1441560
科研通“疑难数据库(出版商)”最低求助积分说明 667885
邀请新用户注册赠送积分活动 654600